Carlsmed, Inc. Common Stock (CARL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Carlsmed, Inc. Common Stock (CARL) has a cash flow conversion efficiency ratio of -0.141x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.01 Million) by net assets ($92.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CARL defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Carlsmed, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how Carlsmed, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Carlsmed, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Carlsmed, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bonava AB (publ)
ST:BONAV-B
|
-0.065x |
|
Anhui Huangshan Capsule Co Ltd
SHE:002817
|
0.046x |
|
Corby Spirit and Wine Limited
TO:CSW-A
|
-0.088x |
|
Zoy Home Furnishing Co Ltd
SHG:603709
|
0.073x |
|
National Aerospace Fasteners Corp
TW:3004
|
-0.010x |
|
Vivotek Inc
TW:3454
|
0.073x |
|
Silver Storm Mining Ltd.
V:SVRS
|
-0.055x |
|
Hunan Zhenghong Science and Technology Develop Co Ltd
SHE:000702
|
-0.064x |
Annual Cash Flow Conversion Efficiency for Carlsmed, Inc. Common Stock (2023–2025)
The table below shows the annual cash flow conversion efficiency of Carlsmed, Inc. Common Stock from 2023 to 2025. For the full company profile with market capitalisation and key ratios, see CARL market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $98.87 Million | $-28.98 Million | -0.293x | -181.29% |
| 2024-12-31 | $-70.63 Million | $-25.47 Million | 0.361x | -4.85% |
| 2023-12-31 | $-46.13 Million | $-17.48 Million | 0.379x | -- |
About Carlsmed, Inc. Common Stock
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and … Read more